Factors associated with aHUS relapse after eculizumab discontinuation in multivariable analysis
| . | OR . | 95% CI . | P . |
|---|---|---|---|
| Analysis including presence of complement gene variant as parameter | |||
| Requirement for dialysis during last aHUS episode before eculizumab discontinuation | 0.17 | 0.03-1.02 | .0560 |
| Female sex | 4.21 | 0.85-20.75 | .0777 |
| Presence of rare variant in complement gene | 16.20 | 1.78-147.73 | .0135 |
| Analysis including sC5b-9 level as parameter | |||
| Requirement for dialysis during last aHUS episode before eculizumab discontinuation | 0.07 | 0.01-0.53 | .0101 |
| Female sex | 10.06 | 1.53-66.19 | .0163 |
| Plasma sC5b-9 ≥300 ng/mL at inclusion | 20.96 | 1.76-250.12 | .0162 |
| . | OR . | 95% CI . | P . |
|---|---|---|---|
| Analysis including presence of complement gene variant as parameter | |||
| Requirement for dialysis during last aHUS episode before eculizumab discontinuation | 0.17 | 0.03-1.02 | .0560 |
| Female sex | 4.21 | 0.85-20.75 | .0777 |
| Presence of rare variant in complement gene | 16.20 | 1.78-147.73 | .0135 |
| Analysis including sC5b-9 level as parameter | |||
| Requirement for dialysis during last aHUS episode before eculizumab discontinuation | 0.07 | 0.01-0.53 | .0101 |
| Female sex | 10.06 | 1.53-66.19 | .0163 |
| Plasma sC5b-9 ≥300 ng/mL at inclusion | 20.96 | 1.76-250.12 | .0162 |
Multivariable analysis could not take into account simultaneously presence of a complement gene variant and increased sC5b-9 level, because of the small sample size (no patient without complement gene variant and with available sC5b-9 level had experienced aHUS relapse after eculizumab discontinuation). Therefore, 2 multivariable analyses were performed. The first included all parameters except for plasma level of sC5b-9 at eculizumab discontinuation. The second included all parameters except for presence of rare variant in complement gene.